Despite numerous therapeutic strategies authorised on the market, survival and quality of life of cancer patients remain as major public health issues . This can be partly explained by the multiplication of agents with the same mechanisms of action, instead of true innovation. There is limited knowledge on how to use anticancer agents for dose, sequence, combination with surgery and/or radiotherapy and duration of treatment . Suboptimal administration of costly treatments may generate unnecessary toxicity for the patients and negatively affects national healthcare budgets.
Establishing treatment optimisation as part of personalised medicine development
Leggi l'articolo originale